STAT3 and neoplasm: The GW4064/cisplatin co-treatment remarkably enhances the chemosensitivity of BTC cells in vitro and inhibits the tumor growth in vivo by the upregulation of SHP expression and the downregulation of STAT3 phosphorylation [209].